Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://sandhill.com](https://www.archivebay.com/archive6/images/7dc7971f-0cc7-4d72-90b1-04977db67134.png)
A complete backup of https://sandhill.com
Are you over 18 and want to see adult content?
![A complete backup of https://aviationsmilitaires.net](https://www.archivebay.com/archive6/images/a0570758-05b0-4646-b1de-da4eaaae1080.png)
A complete backup of https://aviationsmilitaires.net
Are you over 18 and want to see adult content?
![A complete backup of https://berdingnepa.tk](https://www.archivebay.com/archive6/images/9100eb3a-7d3a-413f-b5f0-7febe0f4dd34.png)
A complete backup of https://berdingnepa.tk
Are you over 18 and want to see adult content?
![A complete backup of https://cardanofoundation.org](https://www.archivebay.com/archive6/images/2bf75762-a97c-498e-b2a2-16a546e8ebc6.png)
A complete backup of https://cardanofoundation.org
Are you over 18 and want to see adult content?
![A complete backup of https://rockethomes.com](https://www.archivebay.com/archive6/images/2fd0deca-c7b2-4224-a329-8c7037b9a5fd.png)
A complete backup of https://rockethomes.com
Are you over 18 and want to see adult content?
![A complete backup of https://nsinursingsolutions.com](https://www.archivebay.com/archive6/images/337df062-7e7b-42c2-b354-162b9d8053ba.png)
A complete backup of https://nsinursingsolutions.com
Are you over 18 and want to see adult content?
![A complete backup of https://esbrasil.com.br](https://www.archivebay.com/archive6/images/babbbcab-f04e-4751-9d1b-84472c0584f4.png)
A complete backup of https://esbrasil.com.br
Are you over 18 and want to see adult content?
![A complete backup of https://levelskip.com](https://www.archivebay.com/archive6/images/a61677bd-7ee0-43c2-8335-7568aadbdb13.png)
A complete backup of https://levelskip.com
Are you over 18 and want to see adult content?
![A complete backup of https://brahma.com.br](https://www.archivebay.com/archive6/images/68edc57a-0675-4e71-913f-7d1d526c1a48.png)
A complete backup of https://brahma.com.br
Are you over 18 and want to see adult content?
![A complete backup of https://heritageshores.com](https://www.archivebay.com/archive6/images/ff41435f-1472-4d75-af3b-94af91bf3b12.png)
A complete backup of https://heritageshores.com
Are you over 18 and want to see adult content?
![A complete backup of https://gomtcharleston.com](https://www.archivebay.com/archive6/images/a67da3ed-938e-47ce-9c30-06d3887810ea.png)
A complete backup of https://gomtcharleston.com
Are you over 18 and want to see adult content?
![A complete backup of https://eligma.io](https://www.archivebay.com/archive6/images/577e7767-2bc8-4ee1-8258-f4d46f9b6165.png)
A complete backup of https://eligma.io
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of voiceofwomenafg.blogspot.com](https://www.archivebay.com/archive2/b08b35a5-ffca-459a-9140-d41b90718413.png)
A complete backup of voiceofwomenafg.blogspot.com
Are you over 18 and want to see adult content?
![A complete backup of agungbudisantoso.com](https://www.archivebay.com/archive2/c4cad27c-18b3-4e31-b0aa-ec996616d8e6.png)
A complete backup of agungbudisantoso.com
Are you over 18 and want to see adult content?
![A complete backup of mirlandraskitchen.com](https://www.archivebay.com/archive2/5d65e37a-e6f6-4c78-8d86-210bf9a55365.png)
A complete backup of mirlandraskitchen.com
Are you over 18 and want to see adult content?
![A complete backup of wil-lekstroom.nl](https://www.archivebay.com/archive2/24dec528-bb54-4354-b2ee-2a16f56e2b94.png)
A complete backup of wil-lekstroom.nl
Are you over 18 and want to see adult content?
![A complete backup of recognitionconnect.net](https://www.archivebay.com/archive2/b6bba491-623d-4059-939a-3e770fc6cfed.png)
A complete backup of recognitionconnect.net
Are you over 18 and want to see adult content?
![A complete backup of omanifrankincense.info](https://www.archivebay.com/archive2/6fb84316-a5a3-4d76-95ef-cb69e3b2663e.png)
A complete backup of omanifrankincense.info
Are you over 18 and want to see adult content?
Text
THIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Sascha Rosebush. Sascha brings two decades of legal and compliance experience to her role at Third Rock. As general counsel, she manages all aspects of Third Rock’s legal operations, advises on strategic and tactical initiatives, oversees compliance with federal and state securities laws and regulations and provides advice and support tobusiness personnel.
THIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Sascha Rosebush. Sascha brings two decades of legal and compliance experience to her role at Third Rock. As general counsel, she manages all aspects of Third Rock’s legal operations, advises on strategic and tactical initiatives, oversees compliance with federal and state securities laws and regulations and provides advice and support tobusiness personnel.
THIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Samantha Singer. Samantha focuses on drug discovery and development opportunities at Third Rock. She is honored to be part of a team that has radically improved and saved lives through innovative therapies and diagnostics, and will continue to do so.THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Alison Connors. Alison focuses on strategy and oversight of the financial operations for the funds, management company and early stage portfolio companies. Alison has more than 15 years of financial accounting experience within the biotechnology and life science industries, and she is proud of being a part of the TRV team from thebeginning.
THIRDROCKVENTURES
Charles Homcy. Charles has significant experience building and leading successful biotech companies, and focuses on the formation of companies discovering and developing novel therapeutic approaches. Charles has been a clinical professor of medicine at the University of California, San Francisco Medical School and an attending physician atthe
THIRDROCKVENTURES
Neil Exter. At Third Rock, Neil focuses on the formation, development and strategy of new companies. He has more than 30 years of operating, business development and strategy experience across the spectrum of emerging and established biotechnology and technology companies. Never one to shy away from a challenge, Neil appreciates TRV’s multiTHIRDROCKVENTURES
Tracy has 15 years of recruiting experience specializing in the pharmaceutical and biotechnology industry and has assisted with recruiting for several of the firm’s portfolio companies, including Jounce Therapeutics, Warp Drive Bio and Editas Medicine. Prior to joining Third Rock, she was the human resources manager and recruiterat Agios
THIRDROCKVENTURES
Alan Ezekowitz. Alan is a physician scientist. He spent over 20 years at the Harvard Medical School. He was the Head of the Laboratory of Developmental Immunology and the Head of the MassGeneral Hospital for Children. Alan served on the Partners HealthCare Board. For a decade, as the chief of pediatrics, he reviewed the previous nightsadmissions.
THIRDROCKVENTURES
Walter Kowtoniuk. Walt is passionate about making a difference for patients. He spends his days focused on areas where genetics and genomics bring new insight into disease biology. Walt works where science meets business and strategy, enabling insights from the lab to become the next generation of medicines that can change lives.THIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Sascha Rosebush. Sascha brings two decades of legal and compliance experience to her role at Third Rock. As general counsel, she manages all aspects of Third Rock’s legal operations, advises on strategic and tactical initiatives, oversees compliance with federal and state securities laws and regulations and provides advice and support tobusiness personnel.
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Sascha Rosebush. Sascha brings two decades of legal and compliance experience to her role at Third Rock. As general counsel, she manages all aspects of Third Rock’s legal operations, advises on strategic and tactical initiatives, oversees compliance with federal and state securities laws and regulations and provides advice and support tobusiness personnel.
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Samantha Singer. Samantha focuses on drug discovery and development opportunities at Third Rock. She is honored to be part of a team that has radically improved and saved lives through innovative therapies and diagnostics, and will continue to do so.THIRDROCKVENTURES
Charles Homcy. Charles has significant experience building and leading successful biotech companies, and focuses on the formation of companies discovering and developing novel therapeutic approaches. Charles has been a clinical professor of medicine at the University of California, San Francisco Medical School and an attending physician atthe
THIRDROCKVENTURES
Reid Huber. At Third Rock, Reid brings over 20 years of operating experience in the biotechnology industry to focus on the formation, development and strategy of our portfolio companies. Reid was a member of the founding scientific team at Incyte in 2002, and most recently served as the company’s Executive Vice President and ChiefScientific
THIRDROCKVENTURES
Chris Robinson. Chris leads the recruiting team and executes strategy for our efforts in attracting the top people in the industry to Third Rock and our companies. He is driven by the impact we’re able to have on patients and enjoys being able to be part of the teams that conceptualize grow our companies.THIRDROCKVENTURES
Alan Ezekowitz. Alan is a physician scientist. He spent over 20 years at the Harvard Medical School. He was the Head of the Laboratory of Developmental Immunology and the Head of the MassGeneral Hospital for Children. Alan served on the Partners HealthCare Board. For a decade, as the chief of pediatrics, he reviewed the previous nightsadmissions.
THIRDROCKVENTURES
Tracy Nicholson. Tracy focuses on cross-functional recruiting to build teams within our portfolio companies, as well as performing executive search for the firm. Tracy has 15 years of recruiting experience specializing in the pharmaceutical and biotechnology industry and has assisted with recruiting for several of the firm’s portfolioTHIRDROCKVENTURES
Walter Kowtoniuk. Walt is passionate about making a difference for patients. He spends his days focused on areas where genetics and genomics bring new insight into disease biology. Walt works where science meets business and strategy, enabling insights from the lab to become the next generation of medicines that can change lives.THIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Samantha Singer. Samantha focuses on drug discovery and development opportunities at Third Rock. She is honored to be part of a team that has radically improved and saved lives through innovative therapies and diagnostics, and will continue to do so.THIRDROCKVENTURES
Ton Schumacher. Ton focuses on the formation of novel companies in the immunology and immuno-oncology space. He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University. He was founder of AIMM Therapeutics and T cell factory (acquired by Kite Pharma), and has served as CSO of KitePharma EU.
THIRDROCKVENTURES
Kevin Starr. Kevin co-founded Third Rock with more than 25 years of experience building and leading biotechnology companies. Kevin’s focus has been on the formation, development and strategic governance of our portfolio companies. Kevin met Third Rock co-founders Mark Levin and Bob Tepper while he was chief operating officer and chiefTHIRDROCKVENTURES
Mark Angelino. Mark joined TRV as a venture partner in 2021. He most recently served as Chief Operating Officer at Generation Bio (a non-viral, genetics medicine company), which he co-founded in 2016. From 2012 to 2016, Mark was on the leadership team at bluebird bio, as senior vice president of pharmaceutical sciences and rare diseaseTHIRDROCKVENTURES
Aaron Arvey. Aaron’s role at Third Rock is to advance therapeutic and diagnostic R&D with focused hypothesis-driven machine learning. He enjoys alternating between strategy and technical execution to build data platforms that match scientific strategy. He is motivated by proven impact on patient lives and excited by innovative scientificmethods.
THIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Tracy Nicholson. Tracy focuses on cross-functional recruiting to build teams within our portfolio companies, as well as performing executive search for the firm. Tracy has 15 years of recruiting experience specializing in the pharmaceutical and biotechnology industry and has assisted with recruiting for several of the firm’s portfolioTHIRDROCKVENTURES
Alan Ezekowitz. Alan is a physician scientist. He spent over 20 years at the Harvard Medical School. He was the Head of the Laboratory of Developmental Immunology and the Head of the MassGeneral Hospital for Children. Alan served on the Partners HealthCare Board. For a decade, as the chief of pediatrics, he reviewed the previous nightsadmissions.
THIRDROCKVENTURES
Angelo Severino. Angelo manages Third Rock’s San Francisco office, focusing on operations and administrative support. He enjoys working at Third Rock because of the far-reaching impact of the firm’s portfolio companies, and excited for what the future holds as the firm continues to make exciting, new drug discoveries that will ultimatelyhelp many patients.
THIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Samantha Singer. Samantha focuses on drug discovery and development opportunities at Third Rock. She is honored to be part of a team that has radically improved and saved lives through innovative therapies and diagnostics, and will continue to do so.THIRDROCKVENTURES
Ton Schumacher. Ton focuses on the formation of novel companies in the immunology and immuno-oncology space. He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University. He was founder of AIMM Therapeutics and T cell factory (acquired by Kite Pharma), and has served as CSO of KitePharma EU.
THIRDROCKVENTURES
Kevin Starr. Kevin co-founded Third Rock with more than 25 years of experience building and leading biotechnology companies. Kevin’s focus has been on the formation, development and strategic governance of our portfolio companies. Kevin met Third Rock co-founders Mark Levin and Bob Tepper while he was chief operating officer and chiefTHIRDROCKVENTURES
Aaron Arvey. Aaron’s role at Third Rock is to advance therapeutic and diagnostic R&D with focused hypothesis-driven machine learning. He enjoys alternating between strategy and technical execution to build data platforms that match scientific strategy. He is motivated by proven impact on patient lives and excited by innovative scientificmethods.
THIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Tracy Nicholson. Tracy focuses on cross-functional recruiting to build teams within our portfolio companies, as well as performing executive search for the firm. Tracy has 15 years of recruiting experience specializing in the pharmaceutical and biotechnology industry and has assisted with recruiting for several of the firm’s portfolioTHIRDROCKVENTURES
Walter Kowtoniuk. Walt is passionate about making a difference for patients. He spends his days focused on areas where genetics and genomics bring new insight into disease biology. Walt works where science meets business and strategy, enabling insights from the lab to become the next generation of medicines that can change lives.THIRDROCKVENTURES
Alan Ezekowitz. Alan is a physician scientist. He spent over 20 years at the Harvard Medical School. He was the Head of the Laboratory of Developmental Immunology and the Head of the MassGeneral Hospital for Children. Alan served on the Partners HealthCare Board. For a decade, as the chief of pediatrics, he reviewed the previous nightsadmissions.
THIRDROCKVENTURES
Angelo Severino. Angelo manages Third Rock’s San Francisco office, focusing on operations and administrative support. He enjoys working at Third Rock because of the far-reaching impact of the firm’s portfolio companies, and excited for what the future holds as the firm continues to make exciting, new drug discoveries that will ultimatelyhelp many patients.
THIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Living our core values. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to addressTHIRDROCKVENTURES
Thirdrockventures | Portfolio. Bold Ideas. Big Impact for Patients. We build our companies on a solid foundation, instilling core values and a commitment to great culture. Our companies are based on bold ideas that meet at the intersection of science, business, medicine and strategy - where transformational science meets operational rigorTHIRDROCKVENTURES
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.THIRDROCKVENTURES
Lorence Kim. Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease andautoimmune disease.
THIRDROCKVENTURES
Andrea van Elsas. Andrea van Elsas joined TRV as a venture partner in 2020. He most recently served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded 2011. From 1999 to 2011, he held various positions at Organon (acquired by Schering-Plough and later by Merck) in Oss, TheNetherlands
THIRDROCKVENTURES
Richard Ransohoff. Richard focuses on neuroinflammation research and development opportunities at the firm. He is continually amazed by the raw creativity, commitment, compassion, and intelligence he witnesses at Third Rock. Early in his career, Richard realized how vital his efforts as a neurologist were to patients when, despite ten inches ofTHIRDROCKVENTURES
Mark Levin. Mark co-founded Third Rock with over 40 years of experience, including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and strategic governance of our portfolio companies. Mark contributes as an advisor to our Fund IV portfolio companies and will continue toplay active
THIRDROCKVENTURES
Abbie Celniker. Abbie has over 30 years of experience in Senior R&D and Executive leadership roles, and focuses on the formation, development and strategy of our portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced,diverse teams.
THIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Glenn Pierce. Glenn has more than 30 years of research and development experience working with biotechnology companies. As an entrepreneur-in-residence, Glenn focuses on research, development and translation in hematology across the portfolio. Glenn retired from Biogen in 2014, where he most recently served as chief medical officer, leading theTHIRDROCKVENTURES
Craig Muir. At Third Rock, Craig leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes toTHIRDROCKVENTURES
Samantha Singer. Samantha focuses on drug discovery and development opportunities at Third Rock. She is honored to be part of a team that has radically improved and saved lives through innovative therapies and diagnostics, and will continue to do so.THIRDROCKVENTURES
Ton Schumacher. Ton focuses on the formation of novel companies in the immunology and immuno-oncology space. He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University. He was founder of AIMM Therapeutics and T cell factory (acquired by Kite Pharma), and has served as CSO of KitePharma EU.
THIRDROCKVENTURES
Kevin Starr. Kevin co-founded Third Rock with more than 25 years of experience building and leading biotechnology companies. Kevin’s focus has been on the formation, development and strategic governance of our portfolio companies. Kevin met Third Rock co-founders Mark Levin and Bob Tepper while he was chief operating officer and chiefTHIRDROCKVENTURES
Aaron Arvey. Aaron’s role at Third Rock is to advance therapeutic and diagnostic R&D with focused hypothesis-driven machine learning. He enjoys alternating between strategy and technical execution to build data platforms that match scientific strategy. He is motivated by proven impact on patient lives and excited by innovative scientificmethods.
THIRDROCKVENTURES
Jeffrey Finer. Jeff focuses on drug discovery and development opportunities across our portfolio. Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives,THIRDROCKVENTURES
Tracy Nicholson. Tracy focuses on cross-functional recruiting to build teams within our portfolio companies, as well as performing executive search for the firm. Tracy has 15 years of recruiting experience specializing in the pharmaceutical and biotechnology industry and has assisted with recruiting for several of the firm’s portfolioTHIRDROCKVENTURES
Walter Kowtoniuk. Walt is passionate about making a difference for patients. He spends his days focused on areas where genetics and genomics bring new insight into disease biology. Walt works where science meets business and strategy, enabling insights from the lab to become the next generation of medicines that can change lives.THIRDROCKVENTURES
Alan Ezekowitz. Alan is a physician scientist. He spent over 20 years at the Harvard Medical School. He was the Head of the Laboratory of Developmental Immunology and the Head of the MassGeneral Hospital for Children. Alan served on the Partners HealthCare Board. For a decade, as the chief of pediatrics, he reviewed the previous nightsadmissions.
THIRDROCKVENTURES
Angelo Severino. Angelo manages Third Rock’s San Francisco office, focusing on operations and administrative support. He enjoys working at Third Rock because of the far-reaching impact of the firm’s portfolio companies, and excited for what the future holds as the firm continues to make exciting, new drug discoveries that will ultimatelyhelp many patients.
*
*
*
* Approach
* People
* Portfolio
* Careers
* News
* Contact
* Approach
* People
* Portfolio
* Careers
* News
* Contact
DISCOVER.
LAUNCH.
BUILD.
TRANSFORM.
● RECENT HIGHLIGHTS LIVING OUR CORE VALUES. One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.Learn More
FLARE THERAPEUTICS
Flare Therapeutics is opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.Flare Therapeutics
BLUEBIRD BIO
bluebird bio and Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Abecma® (idecabtagene vicleucel) as the first CAR T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma.bluebird bio
ASHER BIO
Asher Bio is pioneering a new approach with for treating cancer and other diseases with cis‑targeted immunotherapies.Asher Bio
FAZE MEDICINES
Faze is leveraging the groundbreaking new science of biomolecular condensates to develop therapies to slow, halt, or reverse diseasepathology.
Faze Medicines
MOMA THERAPEUTICS
The current era of disease genetics and whole genome profiling have defined molecular machines as the best intervention points in numerous diseases. MOMA's mission is to discover the next generation of precision medicines by targeting the molecular machines that underliediseases.
MOMA Therapeutics
BLUEPRINT MEDICINES
Blueprint received approval from the U.S. Food and Drug Administration (FDA) for GAVRETO™ (pralsetinib) for the treatment of adult patients with RET fusion-positive non-small cell lung cancer and thyroid cancer. This approval brings forward a new standard of care for a genomically defined population of patients that previously had very limited treatment options.Blueprint Medicines
* 1
* 2
* 3
* 4
* 5
* 6
* 7
* 1
* 2
* 3
* 4
* 5
* 6
* 7
0
YEARS
0
PORTFOLIO COMPANIES
0
MARKETED PRODUCTS
0
PRIORITY: PATIENTS
29 Newbury Street
3rd Floor
Boston, MA 02116
P (617) 585-2000
499 Illinois Street
Suite 110
San Francisco, CA 94158P (415) 766-3600
* Privacy Policy
* Terms
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0